BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 25771080)

  • 41. Potential impact of USPSTF recommendations on early diagnosis of breast cancer.
    Aragon R; Morgan J; Wong JH; Lum S
    Ann Surg Oncol; 2011 Oct; 18(11):3137-42. PubMed ID: 21947591
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Uncovering the genomic heterogeneity of multifocal breast cancer.
    Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
    J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast cancer in women in their thirties (2007-2013): a retrospective review.
    Arleo EK; Reichman M; Dashevsky BZ; Babagbemi K; Drotman M
    Breast Dis; 2015; 35(2):87-93. PubMed ID: 25835055
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biennial versus annual mammography and the risk of late-stage breast cancer.
    White E; Miglioretti DL; Yankaskas BC; Geller BM; Rosenberg RD; Kerlikowske K; Saba L; Vacek PM; Carney PA; Buist DS; Oestreicher N; Barlow W; Ballard-Barbash R; Taplin SH
    J Natl Cancer Inst; 2004 Dec; 96(24):1832-9. PubMed ID: 15601639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changes in incidence of in situ and invasive breast cancer by histology type following mammography screening.
    Luke C; Priest K; Roder D
    Asian Pac J Cancer Prev; 2006; 7(1):69-74. PubMed ID: 16629519
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pathological characteristics in screening versus clinically-detected breast cancer].
    Paziault M; Terrade FX; Fermeaux V; Pascal B; Darreye G; Dussartre C; Gilquin M; Labrousse F; Tubiana-Mathieu N
    Bull Cancer; 2006 Jul; 93(7):731-6. PubMed ID: 16873082
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Organized screening detects breast cancer at earlier stage regardless of molecular phenotype.
    Holloway CMB; Jiang L; Whitehead M; Racz JM; Groome PA
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1769-1775. PubMed ID: 29909564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early detection of breast cancer through population-based mammographic screening in Asian women: a comparison study between screen-detected and symptomatic breast cancers.
    Chuwa EW; Yeo AW; Koong HN; Wong CY; Yong WS; Tan PH; Ho JT; Wong JS; Ho GH
    Breast J; 2009; 15(2):133-9. PubMed ID: 19292798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular subtypes of breast cancers detected in mammography screening and outside of screening.
    Sihto H; Lundin J; Lehtimäki T; Sarlomo-Rikala M; Bützow R; Holli K; Sailas L; Kataja V; Lundin M; Turpeenniemi-Hujanen T; Isola J; Heikkilä P; Joensuu H
    Clin Cancer Res; 2008 Jul; 14(13):4103-10. PubMed ID: 18593987
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Breast cancer stromal elastosis is associated with mammography screening detection, low Ki67 expression and favourable prognosis in a population-based study.
    Chen Y; Klingen TA; Wik E; Aas H; Vigeland E; Liestøl K; Garred Ø; Mæhlen J; Akslen LA; Lømo J
    Diagn Pathol; 2014 Dec; 9():230. PubMed ID: 25522915
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens.
    van Luijt PA; Fracheboud J; Heijnsdijk EA; den Heeten GJ; de Koning HJ;
    Eur J Cancer; 2013 Nov; 49(16):3517-25. PubMed ID: 23871248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The comparative value of mammographic screening for women 40-49 years old versus women 50-64 years old.
    Curpen BN; Sickles EA; Sollitto RA; Ominsky SH; Galvin HB; Frankel SD
    AJR Am J Roentgenol; 1995 May; 164(5):1099-103. PubMed ID: 7717212
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does breast screening offer a survival benefit? A retrospective comparative study of oncological outcomes of screen-detected and symptomatic early stage breast cancer cases.
    Újhelyi M; Pukancsik D; Kelemen P; Kovács E; Kenessey I; Udvarhelyi N; Bak M; Kovács T; Mátrai Z
    Eur J Surg Oncol; 2016 Dec; 42(12):1814-1820. PubMed ID: 27424787
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Urban-rural differences in the management of screen-detected invasive breast cancer and ductal carcinoma in situ in victoria.
    Kok DL; Chang JH; Erbas B; Fletcher A; Kavanagh AM; Henderson MA; Gertig DM
    ANZ J Surg; 2006 Nov; 76(11):996-1001. PubMed ID: 17054549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort.
    Puvanesarajah S; Gapstur SM; Gansler T; Sherman ME; Patel AV; Gaudet MM
    Cancer Causes Control; 2020 Jan; 31(1):95-103. PubMed ID: 31802322
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of clinical-pathologic characteristics and outcomes of true interval and screen-detected invasive breast cancer among participants of a Canadian breast screening program: a nested case-control study.
    Rayson D; Payne JI; Abdolell M; Barnes PJ; MacIntosh RF; Foley T; Younis T; Burns A; Caines J
    Clin Breast Cancer; 2011 Mar; 11(1):27-32. PubMed ID: 21421519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do screen-detected breast cancers have positive margins less often than clinically detected breast cancers?
    de Munck L; Siesling S; Bart J; Menke-Pluijmers MB; Otter R; Willemse PH
    Eur J Cancer Prev; 2013 Sep; 22(5):398-403. PubMed ID: 23492953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.
    Obdeijn IM; Winter-Warnars GA; Mann RM; Hooning MJ; Hunink MG; Tilanus-Linthorst MM
    Breast Cancer Res Treat; 2014 Apr; 144(3):577-82. PubMed ID: 24567197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.
    Sayed S; Moloo Z; Wasike R; Bird P; Oigara R; Govender D; Kibera J; Carrara H; Saleh M
    Breast; 2014 Oct; 23(5):591-6. PubMed ID: 25012047
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis.
    Sabatier R; Sabiani L; Zemmour C; Taix S; Chereau E; Gonçalves A; Jalaguier-Coudray A; Charafe-Jauffret E; Resbeut M; Extra JM; Viens P; Tallet A
    Breast; 2016 Jun; 27():8-14. PubMed ID: 27212694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.